ClinicalTrials.gg
WithdrawnNCT07027423Updated Nov 13, 2026

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

A Phase 1 interventional study of BOLD-100 and Doxorubicin 75 mg/m^2 in Sarcoma, Soft-tissue, Sarcoma and Sarcoma,Soft Tissue, sponsored by University Health Network, Toronto. Withdrawn at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University Health Network, Toronto · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Unable to finalize the Clinical Trial Agreement with the drug manufacturer BOLD Therapeutics.
Updated Nov 13, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Sarcoma by University Health Network, Toronto — 6 open to participants now, 7 under way, none of them phase 3. Sarcoma · University Health Network, Toronto.

Enrollment
16th of 16
0 · median 33
Started
2026
the only one that year
Phase 1
6 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Sarcoma by University Health Network, Toronto, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 1, and was the 17th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

6 of the 18 studies in Sarcoma by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sarcoma by University Health Network, Toronto, or all of them as a file.
02

Study summary

A Phase 1b, non-randomized, single-institution trial designed to assess the safety, tolerability and the highest dose with acceptable toxicity (RP2D) of BOLD-100 in combination with doxorubicin in patients diagnosed with advanced soft tissue sarcomas. The trial is divided into two phases: an initial dose-escalation phase for BOLD-100, followed by a dose-expansion phase based on the recommended dose for Phase 2. In the dose-escalation phase, we plan to enroll 12-15 patients, with an additional 17 patients in the dose-expansion phase.

Participants will receive BOLD-100 intravenously on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin (75 mg/m², intravenous) administered on Day 1 of each 21-day cycle for up to six cycles. Participants will continue to receive BOLD-100 for as long as the cancer is not getting worse, The maximum cycles of doxorubicin are 6 cycles.

Participants will undergo a screening assessment prior to the start treatment to determine eligibility for enrollment. Treatment will commence on Day 1 and will continue until the protocol-defined criteria for treatment withdrawal are met. Disease response will be assessed using CT or MRI scans, starting at 12 weeks after the initiation of treatment and continuing every 12 weeks until withdrawal.

Upon treatment discontinuation or study withdrawal, a post-treatment assessment will be conducted at end of treatment and at 30 days of the last BOLD-100 dose, with follow-up visits scheduled every 3 months thereafter.

03

Conditions studied

  • Sarcoma, Soft-tissue
  • Sarcoma
  • Sarcoma,Soft Tissue
  • Sarcomas

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written in accordance with federal, local, and institutional guidelines.
  2. Age > 18 years.
  3. Patients must have confirmed locally advanced/unresectable or soft tissue sarcoma of limited subtype LMS, DDLPS and UPS (including Myxofibrosarcoma-MFS).
  4. Patients be systemic treatment naïve, with incurable, advanced or metastatic disease.
  5. Patient must have as defined by 1.1.
  6. (ECOG) performance status of 0 or 1.
  7. Adequate hematopoietic function:

    1. total white blood cell (WBC) count ≥2000/mm3.
    2. (ANC) ≥1500/mm3.
    3. count ≥100,000/mm3.
  8. Adequate hepatic function:

    1. \<2 times the (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 times ULN).
    2. (ALT) and aspartate aminotransferase (AST) \<2.5 X ULN. In the case of known (radiological and/or documented) liver metastasis, ALT/AST \<5.0 X ULN is acceptable.
  9. Adequate renal function defined as \<1.5x upper limits of normal
  10. Cardiac function: A normal (LVEF) of > 50% as evidenced by an echocardiogram or nuclear medicine study performed within 28 days of the proposed study commencement.
  11. Female patients of must agree to use two methods of (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at 72 hours prior to receiving the first dose of study medication. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.

Exclusion criteria

Exclusion Criteria

Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Patient is pregnant or lactating.
  2. Radiation (except planned or ongoing palliative radiation outside of the region of ), chemotherapy, immunotherapy, any other systemic anticancer therapy, or participation in an anti-cancer study ≤3 weeks prior to initiation of therapy.
  3. Major surgery within 4 weeks before initiation of therapy.
  4. Prior systemic therapy.
  5. Unstable cardiovascular function:

    1. symptomatic ischemia, or.
    2. uncontrolled conduction abnormalities (e.g., ventricular tachycardia on anti-arrhythmic is excluded and 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded) or.
    3. congestive heart failure (CHF) of Class ≥3, or.
    4. myocardial infarction (MI) within 3 months of initiation of therapy.
  6. Active, ongoing or uncontrolled active infection within one week prior to first dose.
  7. other than disease under study within 2 years prior to Cycle 1, Day 1, except for those with a negligible risk of or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Prior chemotherapy is allowed apart from regimens that contained anthracycline based therapies.
  8. Known to be seropositive.
  9. Known active hepatitis A, B, or C infection; or known to be positive for virus (HCV) RNA or virus (HBV) surface antigen (HBsAg).
  10. Patients with active CNS malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.
  11. Serious psychiatric or medical conditions that could interfere with treatment.
  12. Concurrent therapy with approved or investigational anticancer therapeutic agents.
  13. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    BOLD-100 and Doxorubicin Dose Level -1

    Escalation phase DL-1 - BOLD-100 230mg/m\^2 + Doxorubicin

    Drug: BOLD-100 · Drug: Doxorubicin 75 mg/m^2

  • Experimental
    BOLD-100 and Doxorubicin Dose Level 1

    Escalation phase DL1 - BOLD-100 420mg/m\^2 + Doxorubicin

    Drug: BOLD-100 · Drug: Doxorubicin 75 mg/m^2

  • Experimental
    BOLD-100 and Doxorubicin Dose Level 2

    Escalation phase DL2 - BOLD-100 500mg/m\^2 + Doxorubicin

    Drug: BOLD-100 · Drug: Doxorubicin 75 mg/m^2

  • Experimental
    BOLD-100 and Doxorubicin Dose Level 3

    Escalation phase DL3 - BOLD-100 625mg/m\^2 + Doxorubicin

    Drug: BOLD-100 · Drug: Doxorubicin 75 mg/m^2

  • Experimental
    BOLD-100 and Doxorubicin

    Exapsnion: BOLD-100 (RP2D) and Doxorubicin

    Drug: BOLD-100 · Drug: Doxorubicin 75 mg/m^2

Interventions

  • DrugBOLD-100

    BOLD-100 in combination with Doxorubicin (Escalation)

  • DrugDoxorubicin 75 mg/m^2

    Drug page: DoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BOLD-100 in combination with Doxorubicin (Escalation)

  • DrugBOLD-100

    BOLD-100 in combination with Doxorubicin (Expansion)

  • DrugDoxorubicin 75 mg/m^2

    Drug page: DoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BOLD-100 in combination with Doxorubicin (Expansion)

06

What researchers measure

Primary outcomes

  1. The incidence of dose limiting toxicities (DLTs)

    Time frame: Entire duration of Cycle 1 (21 day cycle)

  2. The rate of Adverse Events (AE)

    The rate of Adverse Events (AE) characterized by type, frequency, severity graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0

    Time frame: time the consent form is signed through 12 months following cessation of treatment

  3. Rate of toxicities

    Rate of toxicities as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0, adverse events (AEs), serious AEs (SAEs), dose interruptions and assessment.

    Time frame: time the consent form is signed through 12 months following cessation of treatment.

  4. Participant Quality of Life

    Assessed using EORTC QLQ-C30 (European Organization For Research And Treatment Of Cancer, Core Quality of Life Questionnaire). With scores from 0 to 100. A high scale score represents a higher response level.

    Time frame: pre-dose, Cycle 2 Day1, Cycle 7 Day 1, Cycle 12 Day 1 (21 day cycles)

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS), response rate using RECIST v 1.1, clinical benefit rate (CR, PR, SD \>16 weeks) using the Kaplan Meier method to estimate with corresponding 95% CI

    Time frame: time the consent form is signed through treatment completion, up to 4-6 weeks after progression if applicable

  2. Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100

    Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100 (in the first 3 patients per dose level) using Peak Plasma Concentration (Cmax), which will be compared to single agent population PK of doxorubicin and BOLD-100.

    Time frame: During Cycle 1 pre-dose, 1hour, 2hours and 48hours post-dose, through Cycle 2 pre-dose (21 day cycles)

  3. Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100

    Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100 (in the first 3 patients per dose level) using area under the plasma concentration versus time curve (AUC), which will be compared to single agent population PK of doxorubicin and BOLD-100.

    Time frame: During Cycle 1 pre-dose, 1hour, 2hours and 48hours post-dose, through Cycle 2 pre-dose (21 day cycles)

  4. Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100

    Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100 (in the first 3 patients per dose level) using time to peak drug concentration (Tmax), which will be compared to single agent population PK of doxorubicin and BOLD-100.

    Time frame: During Cycle 1 pre-dose, 1hour, 2hours and 48hours post-dose, through Cycle 2 pre-dose (21 day cycles)

Other outcomes

  1. Correlate cellular morphology and biomarker changes

    Correlate cellular morphology and biomarker changes on sarcoma biopsy specimens compared to archival tissue. Immunohistochemical expression/localization of GRP78.

    Time frame: through study completion, an average of 1 year

  2. Correlate immune signatures and expression of GRP78 levels

    Correlate immune signatures and expression of GRP78 levels in leukocytes in patients' blood with response rate using non-parametric Wilcoxon rank sum.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Jan 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
Jun 18, 2025
StartEst.
Mar 30, 2026
Primary completionEst.
Jan 29, 2027
CompletionEst.
Jan 29, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Unable to finalize the Clinical Trial Agreement with the drug manufacturer BOLD Therapeutics.
changed Nov 13, 2026
Enrollment
32 (estimated)→0 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Withdrawn
    Why stopped Unable to finalize the Clinical Trial Agreement with the drug manufacturer BOLD Therapeutics.
    Enrollment 32 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07027423
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Mar 30, 2026 (estimated)
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion